武田制药(TAK.US)CD38单抗在中国再获批临床

智通财经
17 Dec 2024

智通财经APP获悉,12月16日,中国国家药监局药品审评中心(CDE)网站最新公示,武田制药(TAK.US)1类新药mezagitamab注射剂获得一项新的临床试验默示许可,拟开发治疗原发性免疫性血小板减少症(ITP)。公开资料显示,Mezagitamab是一种全人源免疫球蛋白IgG1单克隆抗体(mAb),对表达CD38的细胞(包括浆母细胞、浆细胞和自然杀伤细胞)具有高亲和力,导致它们的耗竭。Mezagitamab治疗旨在提供快速且持续的血小板应答改善,并恢复血小板计数至功能水平。

截图来源:CDE官网

根据ClinicalTrials官网,武田已经于今年12月启动了mezagitamab治疗成人慢性ITP患者的国际多中心3期临床研究。在中国,武田已经完成该产品治疗持续性/慢性原发性免疫性血小板减少症的2期临床研究。本次该产品再次获得临床试验默示许可,意味着在中国迎来新的进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10